New hope for advanced stomach cancer: experimental drug LM-302 enters final testing phase
NCT ID NCT06351020
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called LM-302 against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has gotten worse after at least two prior therapies. The trial includes 387 adults whose tumors have a specific protein (CLDN18.2) and are HER2-negative. The main goals are to see if LM-302 helps people live longer or slows cancer growth compared to the doctor's choice of standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100000, China
-
Shanghai East Hospital
Shanghai, Shanghai Municipality, 200000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug attack slow down stomach cancer?
- Can a less extensive stomach surgery preserve appetite better?
- Experimental drug combo aims to make inoperable stomach cancers removable
- Smart T-Cell engager aims to outsmart tumors in first human test
- Two-Drug cocktail aims to shrink Hard-to-Treat esophageal and stomach tumors
- Triple attack on stomach cancer: radiation, chemo, and a smart antibody